Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 25, 2015 4:25 PM ET


Company Overview of Polyphor Ltd

Company Overview

Polyphor Ltd. is a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs. Its products include POL6326, an antagonist of the chemokine receptor CXCR4 for stem cell transplantation, tissue repair, and combination treatments in oncology; POL7080, a pseudomonas specific antibiotic with a mode of action to treat pseudomonas infections; and POL6014, an inhaled inhibitor of human neutrophil elastase for the treatment of Alpha-1 antitrypsin deficiency, cystic fibrosis, and other lung diseases. The company also develops solutions for multiple myeloma. Its pipeline of macrocycles also targets leukemia and chronic obstructive pulmonary ...

Hegenheimermattweg 125

Allschwil,  4123


Founded in 1996


41 61 567 16 00


41 61 567 16 01

Key Executives for Polyphor Ltd

Chief Executive Officer
Co-Founder and Chief Scientific Officer
Chief Financial Officer
Head of Technology Platforms
Head of the Internal Services
Compensation as of Fiscal Year 2014.

Polyphor Ltd Key Developments

Polyphor Ltd Presents at UBS Global Healthcare Conference, May-20-2015 12:30 PM

Polyphor Ltd Presents at UBS Global Healthcare Conference, May-20-2015 12:30 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Michael Altorfer, Chief Executive Officer.

Polyphor Ltd. Announces Management Changes

Polyphor Ltd. announced the appointment of Michael Altorfer as new CEO and successor of Jean-Pierre Obrecht as of March 31, 2015. Jean-Pierre Obrecht will continue to support the company in his role as a Member of the Board of Directors. Michael Altorfer joined Polyphor in 2001. He has served Polyphor in various functions, first as Head of the Small Molecule Service Business, then as Chief Financial Officer and Head of Corporate Development, and was Chief Operating Officer since 2014. The company also announced that it recently appointed Leon Hooftman, M.D., as Chief Medical Officer and Adesh Kaul as Head Corporate Development to complement Polyphor's executive management team. Adesh Kaul has extensive experience in the area of corporate-and business development in the Pharma and Biotech industry. Since 2009 he worked at Basilea Pharmaceutica AG, from 2010 as Head Business Development & Investor Relations, from 2009 to 2010 as Head Public Relations & Corporate Communications. Leon Hooftman is an accomplished pharmaceutical physician with more than 20 years of experience in pharmaceutical drug development in the areas of immunology, haematology and oncology, and has several New Drug Applications to his credit. Before joining Polyphor Dr. Hooftman was CMO of Synthon BV.

Polyphor Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015

Polyphor Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.

Similar Private Companies By Industry

Company Name Region
Micro-Macinazione S.A. Europe
FunZyme BioTechnologies S.A. Europe
Amal Therapeutics SA Europe
Dermapharm AG Europe
Galepharm AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Polyphor Ltd, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at